Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- FDA Approves Lenvima for 1st-Line Treatment of Liver Cancer
August 17, 2018
- Maviret Top-Seller Drug in Japan in July: Encise Snapshot
August 17, 2018
- Nesp “Biosame” Could Hit Market as Early as December
August 17, 2018
- Japanese Enrollment Begins for PII Venglustat Study for Gaucher’s Disease: Sanofi Genzyme
August 16, 2018
- Daiichi Sankyo Espha Likely to Roll Out Urief, Iressa Authorized Generics: December Listing
August 16, 2018
- FunPep Begins Joint Research with Osaka Univ. to Boost Development of Antibody-Inducing Peptides Using AI
August 16, 2018
- Intuniv Filed for Adult ADHD: Shionogi/Shire
August 16, 2018
- Astellas Snaps Up UK Gene Therapy Firm Quethera
August 10, 2018
- I/O in Lung Cancer - 1: US Merck Sweeping Frontline NSCLC Space with Keytruda
August 10, 2018
- Takeda Joins Liver-Focused Biotech Launch with US$100 Million Partnership
August 10, 2018
- JCR’s Sakigake-Designated Hunter Syndrome Treatment Enters Japan PIII Study
August 10, 2018
- Mogamulizumab Bags US Approval for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
August 10, 2018
- As Rituxan Biosimilar Enjoys Solid Start, Sandoz Japan Chief Says It’s Important to Be First to Market
August 9, 2018
- Otsuka’s Half-Year Pharma Sales Up 4.1% on Global Brands
August 9, 2018
- Teijin Making Inroads into Biosimilar Arena with Sales Tie-Up for Enbrel Follow-On
August 9, 2018
- Kyorin Holdings President Pledges to Hit Midterm Management Targets; Desalex Performs Better-Than-Expected
August 9, 2018
- Sumitomo Dainippon Chief Rules Out Divestment of Cash-Cow LLPs
August 8, 2018
- Maviret Remains Japan’s Best-Selling Drug in April-June: IQVIA
August 8, 2018
- Ethical Drug Sales Down 4.6% in June: Crecon
August 8, 2018
- Drug Wholesalers Log Sluggish Price Settlement Rates as They Run Careful Negotiations under New Guidelines
August 7, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…